Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Alnylam Pharmaceuticals Inc shares valued at $8,416,730 were sold by Reitan Colleen F on Sep 09 ’25. At $467.60 per share, Reitan Colleen F sold 18,000 shares. The insider’s holdings dropped to 775 shares worth approximately $0.35 million following the completion of this transaction.
Also, Reitan Colleen F purchased 18,000 shares, netting a total of over 8,300,070 in proceeds.
Before that, Tanguler Tolga had sold 3,474 shares from its account. In a trade valued at $1,557,649, the EVP, Chief Commercial Officer traded Alnylam Pharmaceuticals Inc shares for $448.37 each. Upon closing the transaction, the insider’s holdings decreased to 3,474 shares, worth approximately $11.74 million.
As published in a research note from Wolfe Research on August 04, 2025, Alnylam Pharmaceuticals Inc [ALNY] has been rated up from an Underperform to a Peer perform. Analysts at Oppenheimer upgraded the stock from ‘”a Perform”‘ to ‘”an Outperform”‘ outlook in a report released in early August. Earlier on July 21, 2025, Truist initiated its rating. Their recommendation was “a Buy” for ALNY stock.
Analyzing ALNY Stock Performance
On last trading session, Alnylam Pharmaceuticals Inc [NASDAQ: ALNY] plunged -2.06% to $451.73. The stock’s lowest price that day was $450.7, but it reached a high of $463.88 in the same session. During the last five days, there has been a drop of approximately -3.75%. Over the course of the year, Alnylam Pharmaceuticals Inc shares have jumped approximately 70.29%.
Is Alnylam Pharmaceuticals Inc subject to short interest?
Stocks of Alnylam Pharmaceuticals Inc saw a sharp rise in short interest on 2025-08-29 jumping by 0.73 million shares to 3.97 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 3.24 million shares. A jump of 18.5% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.99 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.99.
Which companies own the most shares of Alnylam Pharmaceuticals Inc (ALNY)?
In terms of Alnylam Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 377.5 in the next 12 months, down nearly -18.16% from the previous closing price of $461.24. Analysts anticipate Alnylam Pharmaceuticals Inc stock to reach 470 by 2025, with the lowest price target being 338. In spite of this, 20 analysts ranked Alnylam Pharmaceuticals Inc stock as Buy at the end of 2025. On March 31, 2025, Redburn Atlantic assigned a price target of “a Buy” to the stock and initiated coverage with a $353.
